Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma
Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of...
Gespeichert in:
| Veröffentlicht in: | Transfusion and apheresis science 2021-06, Vol.60 (3), p.103104-103104, Article 103104 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103104 |
|---|---|
| container_issue | 3 |
| container_start_page | 103104 |
| container_title | Transfusion and apheresis science |
| container_volume | 60 |
| creator | Ormazabal Vélez, Irati Induráin Bermejo, Juan Espinoza Pérez, José Imaz Aguayo, Laura Delgado Ruiz, Marina García-Erce, José Antonio |
| description | Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse. |
| doi_str_mv | 10.1016/j.transci.2021.103104 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7894088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473050221000628</els_id><sourcerecordid>2494305180</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-696ee0244e54f9c1ed07ccd0e3e1f9a0f9c71c1cffa598cece57e80334aa17443</originalsourceid><addsrcrecordid>eNqFUcGO0zAQtRCIXQqfAPKRS4odO3FyAaEVC0grcVnO1tSZdF05drCdFo78-brbsoITJ1szb957M4-Q15ytOePtu906R_DJ2HXNal5qgjP5hFzyTnUVbzvxtPylEhVrWH1BXqS0Y4wr3rfPyYUQrVCyVZfk9-0h0BmyRZ8TPdh8R6PNy087wYZCSsFYyDhQFw50C9MEWxc2i7OeOtyjSxT8QCM6mFNBmbC3Q8V7av2IJtvgE80RHxgeuE3we3CYTJGjs4M0wUvybASX8NX5XZHv159ur75UN98-f736eFOZYjRXbd8islpKbOTYG44DU8YMDAXysQdWaoobbsYRmr4zaLBR2DEhJABXUooVeX_inZfNhMPRQQSn51hWjb90AKv_7Xh7p7dhr1XXS9Z1heDtmSCGHwumrCdbFnEOPIYl6Vr2UrCGF9EVaU5QE0NKEcdHGc70MT690-f49DE-fYqvzL352-Pj1J-8CuDDCVBOj3uLURcK9AYHG8vB9RDsfyTuAT8Es4k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494305180</pqid></control><display><type>article</type><title>Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ormazabal Vélez, Irati ; Induráin Bermejo, Juan ; Espinoza Pérez, José ; Imaz Aguayo, Laura ; Delgado Ruiz, Marina ; García-Erce, José Antonio</creator><creatorcontrib>Ormazabal Vélez, Irati ; Induráin Bermejo, Juan ; Espinoza Pérez, José ; Imaz Aguayo, Laura ; Delgado Ruiz, Marina ; García-Erce, José Antonio</creatorcontrib><description>Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>EISSN: 1473-0502</identifier><identifier>DOI: 10.1016/j.transci.2021.103104</identifier><identifier>PMID: 33637467</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Convalescent plasma ; COVID-19 ; Health technology assessment ; Hypogammaglobulinemia ; Rituximab</subject><ispartof>Transfusion and apheresis science, 2021-06, Vol.60 (3), p.103104-103104, Article 103104</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-696ee0244e54f9c1ed07ccd0e3e1f9a0f9c71c1cffa598cece57e80334aa17443</citedby><cites>FETCH-LOGICAL-c467t-696ee0244e54f9c1ed07ccd0e3e1f9a0f9c71c1cffa598cece57e80334aa17443</cites><orcidid>0000-0001-7662-6286 ; 0000-0003-0119-329X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transci.2021.103104$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33637467$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ormazabal Vélez, Irati</creatorcontrib><creatorcontrib>Induráin Bermejo, Juan</creatorcontrib><creatorcontrib>Espinoza Pérez, José</creatorcontrib><creatorcontrib>Imaz Aguayo, Laura</creatorcontrib><creatorcontrib>Delgado Ruiz, Marina</creatorcontrib><creatorcontrib>García-Erce, José Antonio</creatorcontrib><title>Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma</title><title>Transfusion and apheresis science</title><addtitle>Transfus Apher Sci</addtitle><description>Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.</description><subject>Convalescent plasma</subject><subject>COVID-19</subject><subject>Health technology assessment</subject><subject>Hypogammaglobulinemia</subject><subject>Rituximab</subject><issn>1473-0502</issn><issn>1878-1683</issn><issn>1473-0502</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFUcGO0zAQtRCIXQqfAPKRS4odO3FyAaEVC0grcVnO1tSZdF05drCdFo78-brbsoITJ1szb957M4-Q15ytOePtu906R_DJ2HXNal5qgjP5hFzyTnUVbzvxtPylEhVrWH1BXqS0Y4wr3rfPyYUQrVCyVZfk9-0h0BmyRZ8TPdh8R6PNy087wYZCSsFYyDhQFw50C9MEWxc2i7OeOtyjSxT8QCM6mFNBmbC3Q8V7av2IJtvgE80RHxgeuE3we3CYTJGjs4M0wUvybASX8NX5XZHv159ur75UN98-f736eFOZYjRXbd8islpKbOTYG44DU8YMDAXysQdWaoobbsYRmr4zaLBR2DEhJABXUooVeX_inZfNhMPRQQSn51hWjb90AKv_7Xh7p7dhr1XXS9Z1heDtmSCGHwumrCdbFnEOPIYl6Vr2UrCGF9EVaU5QE0NKEcdHGc70MT690-f49DE-fYqvzL352-Pj1J-8CuDDCVBOj3uLURcK9AYHG8vB9RDsfyTuAT8Es4k</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Ormazabal Vélez, Irati</creator><creator>Induráin Bermejo, Juan</creator><creator>Espinoza Pérez, José</creator><creator>Imaz Aguayo, Laura</creator><creator>Delgado Ruiz, Marina</creator><creator>García-Erce, José Antonio</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7662-6286</orcidid><orcidid>https://orcid.org/0000-0003-0119-329X</orcidid></search><sort><creationdate>20210601</creationdate><title>Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma</title><author>Ormazabal Vélez, Irati ; Induráin Bermejo, Juan ; Espinoza Pérez, José ; Imaz Aguayo, Laura ; Delgado Ruiz, Marina ; García-Erce, José Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-696ee0244e54f9c1ed07ccd0e3e1f9a0f9c71c1cffa598cece57e80334aa17443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Convalescent plasma</topic><topic>COVID-19</topic><topic>Health technology assessment</topic><topic>Hypogammaglobulinemia</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ormazabal Vélez, Irati</creatorcontrib><creatorcontrib>Induráin Bermejo, Juan</creatorcontrib><creatorcontrib>Espinoza Pérez, José</creatorcontrib><creatorcontrib>Imaz Aguayo, Laura</creatorcontrib><creatorcontrib>Delgado Ruiz, Marina</creatorcontrib><creatorcontrib>García-Erce, José Antonio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ormazabal Vélez, Irati</au><au>Induráin Bermejo, Juan</au><au>Espinoza Pérez, José</au><au>Imaz Aguayo, Laura</au><au>Delgado Ruiz, Marina</au><au>García-Erce, José Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma</atitle><jtitle>Transfusion and apheresis science</jtitle><addtitle>Transfus Apher Sci</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>60</volume><issue>3</issue><spage>103104</spage><epage>103104</epage><pages>103104-103104</pages><artnum>103104</artnum><issn>1473-0502</issn><eissn>1878-1683</eissn><eissn>1473-0502</eissn><abstract>Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation. They developed important respiratory and neurological complications. After CP infusion, neutralising antibodies were detected and viral load dissapeared in both patients leading to clinical improvement with no more Covid-19 relapse.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33637467</pmid><doi>10.1016/j.transci.2021.103104</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7662-6286</orcidid><orcidid>https://orcid.org/0000-0003-0119-329X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-0502 |
| ispartof | Transfusion and apheresis science, 2021-06, Vol.60 (3), p.103104-103104, Article 103104 |
| issn | 1473-0502 1878-1683 1473-0502 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7894088 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Convalescent plasma COVID-19 Health technology assessment Hypogammaglobulinemia Rituximab |
| title | Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T08%3A59%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20patients%20with%20rituximab%20associated%20low%20gammaglobulin%20levels%20and%20relapsed%20covid-19%20infections%20treated%20with%20convalescent%20plasma&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Ormazabal%20V%C3%A9lez,%20Irati&rft.date=2021-06-01&rft.volume=60&rft.issue=3&rft.spage=103104&rft.epage=103104&rft.pages=103104-103104&rft.artnum=103104&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/j.transci.2021.103104&rft_dat=%3Cproquest_pubme%3E2494305180%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2494305180&rft_id=info:pmid/33637467&rft_els_id=S1473050221000628&rfr_iscdi=true |